[Chinese expert consensus on the diagnosis and treatment of polycythemia vera (2016)]

[Article in Chinese]

[Article in Chinese]

Leukemia and Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Zhonghua Xue Ye Xue Za Zhi. 2016 Apr.

. 2016 Apr;37(4):265-8.

doi: 10.3760/cma.j.issn.0253-2727.2016.04.001.

No abstract available

References

1. 徐俊卿, 徐泽锋, 王静雅, et al. 615例Ph染色体/BCR-ABL融合基因阴性骨髓增殖性肿瘤患者的症状负荷评估[J] 中华血液学杂志. 2016;37(1):26–29. doi: 10.3760/cma.j.issn.0253-2727.2016.01.005. - DOI
1. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical Concepts and management recommendations from European LeukemiaNet[J] J Clin Oncol. 2011;29(6):761–770. doi: 10.1200/JCO.2010.31.8436. - DOI - PMC - PubMed
1. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis[J] N Engl J Med. 2007;356(5):459–468. doi: 10.1056/NEJMoa065202. - DOI - PMC - PubMed
1. Bench AJ, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations[J] Br J Haematol. 2013;160(1):25–34. doi: 10.1111/bjh.12075. - DOI - PubMed
1. 肖志坚. 骨髓增殖性肿瘤和骨髓增生异常综合征/骨髓增殖性肿瘤:开启分子诊断新时代[J] 中华血液学杂志. 2014;35(5):385–386. doi: 10.3760/cma.j.issn.0253-2727.2014.05.001. - DOI